
==== Front
Sci Rep
Sci Rep
Scientific Reports
2045-2322
Nature Publishing Group UK London

39237611
71476
10.1038/s41598-024-71476-2
Article
Genetic variants regulating the immune response improve the prediction of COVID-19 severity provided by clinical variables
Delgado-Wicke Pablo 1
Fernández de Córdoba-Oñate Sara 21617
Roy-Vallejo Emilia 3
Alegría-Carrasco Estíbaliz 1
Rodríguez-Serrano Diego A. 4
Lamana Amalia 5
Montes Nuria 2618
Nicolao-Gómez Ana 1
Carracedo-Rodríguez Rosa 1
Marcos-Jiménez Ana 7
Díaz-Fernández Paula 7
Galván-Román José M. 3
Rabes-Rodríguez Laura 3
Sanz-Alba Marta 3
Álvarez-Rodríguez Jesús 3
Villa-Martí Almudena 3
Rodríguez-Franco Carlos 3
Villapalos-García Gonzalo 89
Zubiaur Pablo 89
Abad-Santos Francisco 89
de los Santos Ignacio 311
Gomariz Rosa P. 5
García-Vicuña Rosario 210
Muñoz-Calleja Cecilia 71011
González-Álvaro Isidoro isidoro.ga@ser.es

2
Fernández-Ruiz Elena efruiz@salud.madrid.org

110
PREDINMUN-COVID GroupSuárez Fernández Carmen 3
Barrios Ana 3
Sanz Jesús 3
Casado Pedro 3
Gutiérrez Ángela 3
Bautista Azucena 3
Hernández Pilar 3
Ruiz Giménez Nuria 3
Moyano Berta 3
Gil Paloma 3
Delgado María Jesús 3
Parra Pedro 3
Sánchez Beatriz 3
Sáez Carmen 3
Fernández-Rico Marta 3
Arévalo-Román Cristina 3
Ciudad Marianela 3
Castañeda Santos 2
Llorente Irene 2
Tomero Eva G. 2
García-Castañeda Noelia 2
Uriarte Miren 2
Cardeñoso Laura 12
Fontán García-Rodrigo Leticia 12
García Diego Domingo 12
Alarcón-Cavero Teresa 12
Semiglia Chong María Auxiliadora 12
Gutiérrez-Cobos Ainhoa 12
Zurita-Cruz Nelly D. 12
Sánchez-Madrid Francisco 7
Martín-Gayo Enrique 7
Sánchez-Cerrillo Ildefonso 7
Martínez-Fleta Pedro 7
López-Sanz Celia 7
Gabrie Ligia 7
del Campo-Guerola Luciana 7
Tejedor Reyes 7
Ancochea Julio 13
García-Castillo Elena 13
Ávalos Elena 13
Sánchez-Azofra Ana 13
Alonso Tamara 13
Cisneros Carolina 13
Valenzuela Claudia 13
García-Pérez Francisco J. 13
Girón Rosa M. 13
Aspa Javier 13
Marcos Celeste 13
del Perpetuo Socorro Churruca M. 13
Zamora Enrique 13
Martínez Adrián 13
Barrio-Mayo Mar 13
Henares-Espi Rosalina 13
Méndez Rosa 14
Arribas David 14
Chicot-Llano Marta 4
González Begoña 4
Quicios Begoña 4
Patiño Pablo 4
Trigueros Marina 4
Dominguez-Peña Cristina 4
Jiménez-Jiménez David 4
Villamayor Pablo 4
Canabal Alfonso 4
de la Cámara Rafael 15
Ortiz Javier 15
Iturrate Isabel 15

1 https://ror.org/03cg5md32 grid.411251.2 0000 0004 1767 647X Molecular Biology Unit, Hospital Universitario La Princesa and Health Research Institute (IIS-Princesa), Madrid, Spain
2 https://ror.org/01s1q0w69 grid.81821.32 0000 0000 8970 9163 Rheumathology Department, Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
3 https://ror.org/01s1q0w69 grid.81821.32 0000 0000 8970 9163 Internal Medicine Department, Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
4 grid.411251.2 0000 0004 1767 647X Intensive Care Unit, Hospital Universitario La Princesa (IIS Princesa), Madrid, Spain
5 https://ror.org/02p0gd045 grid.4795.f 0000 0001 2157 7667 Cell Biology Department, Facultad de Biología, Universidad Complutense de Madrid, Madrid, Spain
6 https://ror.org/00tvate34 grid.8461.b 0000 0001 2159 0415 Pharmaceutical and Health Sciences Department, Faculty of Pharmacy, Universidad San Pablo-CEU, Boadilla del Monte, Spain
7 https://ror.org/01s1q0w69 grid.81821.32 0000 0000 8970 9163 Immunology Department, Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
8 https://ror.org/01s1q0w69 grid.81821.32 0000 0000 8970 9163 Clinical Pharmacology Department, Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
9 https://ror.org/01cby8j38 grid.5515.4 0000 0001 1957 8126 Pharmacology Department, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
10 https://ror.org/01cby8j38 grid.5515.4 0000 0001 1957 8126 Medicine Department, Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, Spain
11 https://ror.org/00ca2c886 grid.413448.e 0000 0000 9314 1427 Centro de Investigación Biomédica en Red en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain
12 https://ror.org/01s1q0w69 grid.81821.32 0000 0000 8970 9163 Microbiology Department, Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
13 https://ror.org/01s1q0w69 grid.81821.32 0000 0000 8970 9163 Pneumology Department, Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
14 https://ror.org/01s1q0w69 grid.81821.32 0000 0000 8970 9163 Anesthesiology Department, Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
15 https://ror.org/01s1q0w69 grid.81821.32 0000 0000 8970 9163 Hematology Department, Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
16 https://ror.org/0111es613 grid.410526.4 0000 0001 0277 7938 Present Address: Hematology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
17 grid.410526.4 0000 0001 0277 7938 Present Address: Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Madrid, Spain
18 https://ror.org/01s1q0w69 grid.81821.32 0000 0000 8970 9163 Present Address: Methodology Department, Hospital Universitario La Princesa (IIS-Princesa), Madrid, Spain
5 9 2024
5 9 2024
2024
14 2072814 12 2023
28 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
The characteristics of the host are crucial in the final outcome of COVID-19. Herein, the influence of genetic and clinical variants in COVID-19 severity was investigated in a total of 1350 patients. Twenty-one single nucleotide polymorphisms of genes involved in SARS-CoV-2 sensing as Toll-like-Receptor 7, antiviral immunity as the type I interferon signalling pathway (TYK2, STAT1, STAT4, OAS1, SOCS) and the vasoactive intestinal peptide and its receptors (VIP/VIPR1,2) were studied. To analyse the association between polymorphisms and severity, a model adjusted by age, sex and different comorbidities was generated by ordinal logistic regression. The genotypes rs8108236-AA (OR 0.12 [95% CI 0.02–0.53]; p = 0.007) and rs280519-AG (OR 0.74 [95% CI 0.56–0.99]; p = 0.03) in TYK2, and rs688136-CC (OR 0.7 [95% CI 0.5–0.99]; p = 0.046) in VIP, were associated with lower severity; in contrast, rs3853839-GG in TLR7 (OR 1.44 [95% CI 1.07–1.94]; p = 0.016), rs280500-AG (OR 1.33 [95% CI 0.97–1.82]; p = 0.078) in TYK2 and rs1131454-AA in OAS1 (OR 1.29 [95% CI 0.95–1.75]; p = 0.110) were associated with higher severity. Therefore, these variants could influence the risk of severe COVID-19.

Subject terms

Clinical genetics
Genetic markers
Immunogenetics
Medical genetics
Population genetics
Infectious diseases
Immunogenetics
Infection
Infectious diseases
Genetics
Immunology
Biomarkers
Prognostic markers
Ministerio de Economía y Competitividad (Instituto de Salud Carlos III)PI19/00096 PI18/0371 PI19/00096 Delgado-Wicke Pablo González-Álvaro Isidoro Fernández-Ruiz Elena Banco Santander and CRUE"Fondos Supera COVID19" "Fondos Supera COVID19" "Fondos Supera COVID19" Fernández de Córdoba-Oñate Sara Gomariz Rosa P. Muñoz-Calleja Cecilia INSTITUTO DE SALUD CARLOS III. Rio Hortega GrantCM19/00149 CM19/00254 Roy-Vallejo Emilia Marcos-Jiménez Ana European Union's Recovery. Ministerio de Ciencia e Innovación. INVESTIGO2022-C23.I01.P03.S0020-0000031 Alegría-Carrasco Estíbaliz European Union's Recovery. Comunidad Autónoma de Madrid. INVESTIGO09-PIN1-00015.6/2022 Nicolao-Gómez Ana Ministerio de Ciencia e Innovación (Instituto de 391 Salud Carlos III, ISCIII) and co-funded by The ERDF "A way to make Europe"FI19/00092 FI20/00090 Díaz-Fernández Paula Villapalos-García Gonzalo http://dx.doi.org/10.13039/501100004593 Universidad Autónoma de Madrid Margarita Salas Zubiaur Pablo RICORS and Ministerio de Ciencia e Innovación (Instituto de Salud Carlos III, ISCIII), co-funded by European Regional Development Fund (ERDF) "A way to make Europe”; and co-financed by the Community of Madrid (CAM) through the COVID 2019 AidRD21/0002/0004 RD21/0002/0004 de los Santos Ignacio Gomariz Rosa P. RED DE ENFERMEDADES INFLAMATORIAS ‐ RICORSRD21/0002/0027 González-Álvaro Isidoro issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

The clinical heterogeneity of COVID-19 ranges from asymptomatic infection to an exacerbated inflammatory response1,2. There are several host factors that can affect the severity of COVID-19 as age, sex and several comorbidities including hypertension, diabetes or heart disease3,4. However, early in the evolution of the pandemic it was evidenced that those cases with severe forms of COVID-19 were related with an exacerbated immune response to the virus, leading to an hyperinflammatory status and, in the worst cases, a devastating effect on the lungs denominated Acute Respiratory Distress Syndrome (ARDS)5, thrombosis and multiple organ failure6,7.

The innate immune system plays an essential role in the antiviral response and rapidly senses viral infection through Toll-like receptors (TLRs) triggering type I interferon (IFN) production8. Among TLRs, the endosomal TLR7 recognizes single strand RNA viruses as SARS-CoV-29–11. The effectiveness of the early immune response depends on the capability of cells to induce a competent expression of a variety of interferon-stimulated genes (ISGs) involved in the orchestration of the antiviral response and immune-regulation12,13. This process needs a fine coordination led by receptors and cellular mediators, as the Janus kinase and Signal transducers and activators of transcription (JAK-STAT) signalling pathway, whose participation is essential and whose deregulation has already been related to susceptibility to infections and the development of autoimmune diseases14–16. In addition, the vasoactive intestinal peptide (VIP) and its G protein-coupled receptors VPAC1 and VPAC2 modulate the immune response in several immune-mediated inflammatory disorders (IMID)17–19 and viral infections20, and its relationship with severe COVID-19 is an active area of research. A patented formulation of VIP RLF-100 (Aviptadil) is now under clinical trials to evaluate its use for COVID-19-related ARDS. Preliminary results showed that this treatment increases life expectancy by optimizing oxygenation and controlling the failure caused by the COVID-19 induced cytokine storm21.

Genome-wide association studies (GWAS) have tried to identify genetic factors related to COVID-19 severity, and single nucleotide polymorphisms (SNPs) of several loci integrated in the pathway of virus entry into the cells have been reported22. Among them, previous work of our group has validated the transmembrane serine protease 2 (TMPRSS2 rs75603675) as a predictor of the severity of hospitalized patients23. Moreover, TMPRSS2 rs713400 was associated with SARS-CoV-2 viremia and a poor prognosis24. Furthermore, different gene pathways of activation and regulation of the immune response have been assessed, and missense variants either in the viral RNA sensor TLR7 or in the IFN α/β-receptor (IFNAR1/2) have been associated to severe cases of COVID-1925–28. Autosomal-recessive deficiencies in the intracellular mediators of the IFNAR1 signalling pathway, as tyrosine kinase 2 (TYK2) or STAT family members, favour intracellular bacterial and viral infections through impaired cytokine response29–31. Consequently, missense genetic variants of these genes participate in COVID-19 severity28,32,33. However, genetic variants leading to high expression of TYK2 are associated to critical COVID-19 disease34 and the inhibition of this tyrosine kinase has been proposed as a therapeutic target in influenza A virus infections aggravated by secondary bacterial pneumonia35.

Because of the disparity of observed findings, additional confirmatory and exploratory studies are warranted. Therefore, in this observational study we validated previously reported alleles and evaluated new SNP candidates in TLR7, TYK2 and downstream interferon-stimulated genes (ISGs) as STAT1, STAT4, OAS1 (2'-5' oligoadenylate synthetase 1) and SOCS1 (suppressor of cytokine signalling 1), as well as VIP, VIPR1 and VIPR2 genes, determining their potential worsening or protective role in the outcome of COVID-19. For this purpose, first, a clinical model was developed with the characteristics and comorbidities associated with COVID-19 severity in our cohort (age, sex, cancer, dementia, diabetes, hypertension, obesity and people living with HIV). Then, each SNP was added to the clinical model and evaluated and, finally, those variants with a significant association were selected for a combined clinical and genetic model. We found that genetic variants in TYK2 (rs8108236-AA and rs280519-AG) and VIP (rs688136-CC) had a protective role, while other variants in TYK2 (rs280500-AG), TLR7 (rs3853839-GG) and OAS1 (rs1131454-AA) increased the likelihood of developing greater COVID-19 severity.

Results

Sociodemographic and clinical variables associated with COVID-19 severity in our population

A total of 1,440 patients were genotyped. Twenty-six of them were excluded from the statistical analysis due to genotyping failure (more than 5% missing genotypes), while 64 were excluded because of missing relevant clinical data. Therefore, a total of 1,350 patients were included in the study, with a mean age of 63.3 years (SD 16.7), 55.6% were male and 82.1% white non-Hispanic. The main comorbidities detected in the population were hypertension (41%) and dyslipidaemia (37%). Regarding severity (see Materials and Methods for definition), 31.4% of patients were classified as having mild, 45.5% moderate and 23.1% severe disease. There were significant differences between severity groups in terms of age (p < 0.001), male sex (p < 0.001), prevalence of hypertension (p < 0.001), dyslipidaemia (p < 0.001), diabetes mellitus (p < 0.001), obesity (p = 0.002), dementia (p < 0.001), cancer (p = 0.001) and people living with HIV (LHIV) (p < 0.001), as shown in Table 1. Treatment administered and analytical data collected during hospitalization are listed in Table S1. Table 1 Demographic and clinical data according to COVID-19 severity scale.

Variable	n	Mild,
n = 424a	Moderate,
n = 614a	Severe,
n = 312a	Pb	
Sex x Age (years)	1350				 < 0.001	
 Female < 45		69 (16%)	19 (3.1%)	4 (1.3%)		
 Female 45–70		118 (28%)	130 (21%)	32 (10%)		
 Female > 70		32 (7.5%)	129 (21%)	67 (21%)		
 Male < 45		51 (12%)	42 (6.8%)	9 (2.9%)		
 Male 45–70		123 (29%)	177 (29%)	94 (30%)		
 Male > 70		31 (7.3%)	117 (19%)	106 (34%)		
Race/ethnicity	1349				0.3	
 White, non-Hispanic		345 (81%)	497 (81%)	266 (85%)		
 White, Hispanic		74 (17%)	109 (18%)	40 (13%)		
 Afro-descendent		1 (0.2%)	0 (0%)	1 (0.3%)		
 Asian		4 (0.9%)	7 (1.1%)	5 (1.6%)		
 Missing		0	1	0		
Hypertension	1350				 < 0.001	
 Yes		94 (22%)	269 (44%)	178 (57%)		
Diabetes mellitus	1350				 < 0.001	
 No		394 (93%)	500 (81%)	237 (76%)		
 Without organ damage		26 (6.1%)	102 (17%)	55 (18%)		
 With organ damage		4 (0.9%)	12 (2.0%)	20 (6.4%)		
Dyslipidaemia	1350				 < 0.001	
 Yes		102 (24%)	250 (41%)	147 (47%)		
Obesity	1350				0.002	
 Yes		39 (9.2%)	89 (14%)	56 (18%)		
Dementia	1350				 < 0.001	
 Yes		5 (1.2%)	25 (4.1%)	25 (8.0%)		
Cancer	1350				0.001	
 No		419 (99%)	594 (97%)	291 (93%)		
 Without metastasis		3 (0.7%)	15 (2.4%)	14 (4.5%)		
 With metastasis		2 (0.5%)	5 (0.8%)	7 (2.2%)		
People living with HIV	1350				 < 0.001	
 Yes		25 (5.9%)	4 (0.7%)	0 (0%)		
an (%).

bPearson's Chi-squared test; Fisher's exact test.

When the multivariate analysis was performed to establish the clinical variables predicting severity, only some of them remained statistically significant. Among these variables, the interaction between sex and age was included to improve model adjustment. This interaction indicated that the risk increased in older age groups and was higher in males than in females. The risk of severe clinical outcome was also increased to different extents by other known comorbidities such as hypertension, obesity, dementia, diabetes (being higher for patients with organ damage) and cancer (being higher for metastatic cancer). In contrast, living with HIV exhibited a protective role notably decreasing COVID-19 severity. This multivariate model was used to adjust the association between genetic variants and COVID-19 severity (Table 2). Table 2 Clinical model with demographic and clinical variables of the patients.

Variable	OR	95% CI	p-value	
Interaction of sex and age (comparator: females under 45 y.o.)	
 Female 45–70 y.o	3.76	2.25–6.5	 < 0.001	
 Female > 70 y.o	9.98	5.74–17.85	 < 0.001	
 Male < 45 y.o	3.6	1.97–6.73	 < 0.001	
 Male 45–70 y.o	7.25	4.37–12.41	 < 0.001	
 Male > 70 y.o	14.87	8.55–26.61	 < 0.001	
People living with HIV	0.08	0.02–0.21	 < 0.001	
Diabetes (comparator: no)	
 Without organ damage	1.2	0.88–1.64	0.253	
 With organ damage	2.31	1.17–4.69	0.018	
Dementia	1.85	1.07–3.2	0.027	
Obesity	1.6	1.17–2.19	0.004	
Hypertension	1.45	1.13–1.86	0.003	
Cancer (comparator: no)	
 Without metastasis	1.72	0.87–3.45	0.121	
 With metastasis	3.61	1.23–11.02	0.02	
n: 1350; AIC: 2587.679; R2 McFadden: 0.106; R2 Nagelkerke: 0.230.

CI confidence interval, OR Odds ratio y.o. years old.

Genotyping and association analysis with clinical variables

Genotype analysis was performed for 21 SNPs within genes involved in the intracellular sensing of SARS-CoV-2 as TLR7, the IFN-I signalling pathway (TYK2, STAT1, STAT4, OAS1, SOCS1) and the VIP/VPAC axis. The studied SNPs were not in linkage disequilibrium (LD) and their minor allele frequency (MAF) was > 0.01 (Table S2). In the case of TYK2, due to its upstream position in the IFN-I pathway, seven SNPs covering the gene were analysed (Fig S1).

To determine the association between each SNP and COVID-19 severity, the 21 SNPs were included separately in the clinical model by multivariate analysis and TYK2 rs8108236, rs280519 and rs280500, OAS1 rs1131454, TLR7 rs3853839 and VIP rs688136 remained significant. The predicted probability of severity per genotype of significant SNPs in this model is shown in Fig. 1. This analysis showed that the rs280519-GA, rs8108236-AA and rs688136-CC genotypes were protective compared to each of their major alleles (Odds ratio, OR = 0.786/0.171/0.682, respectively) (Fig. 1, upper panels), while carrying rs1131454-AA, rs3853839-GG or rs280500-AG was considered a risk factor (OR = 1.323/1.478/1.104, respectively) (Fig. 1, lower panels).Fig. 1 Predicted probability of COVID-19 severity for each significant SNP in the clinical model. Numbers inside each graph bar indicate the predicted probability of COVID-19 severity as percentage (95% confidence interval) for each genotype: OAS1 rs1131454, TLR7 rs3853839, TYK2 rs280500, rs280519 and rs8108236, and VIP rs688136. Upper horizontal lines indicate significant p-values and Odds ratios from the multivariable analysis in which each SNP was included separately in the clinical model.

Then, the combined effect or influence of these SNPs and clinical variables on COVID-19 severity was analysed (Fig. 2). Although clinical variables strongly influenced the disease outcome, showing higher OR compared to genetic variants, TYK2 rs8108236-AA, rs280519-AG and VIP rs688136-CC genotypes were associated with a lower COVID-19 severity (OR < 1) and TLR7 rs3853839-GG, TYK2 rs280500-AG and OAS1 rs1131454-AA genotypes favoured a worse disease outcome (OR > 1). Among them, the TLR7 rs3853839-GG genotype had the highest OR value (OR = 1.44). This model resulting from including these variants was statistically different from the model that only included clinical variables (p < 0.001). The model combining both genetic variants and clinical variables provided a better explanation of data variability (R2 Nagelkerke from 0.230 to 0.250) and improved the prediction of disease severity (R2 McFadden from 0.106 to 0.117).Fig. 2 Forest plot of the final multivariable model with clinical and genetic variables. The Odds ratios (dots) and 95% confidence intervals (horizontal bars) for all variables are depicted. ORs = 1 correspond to reference conditions and are represented by grey dots, as well as non-significant conditions. Conditions that significantly increase the probability of developing severe COVID-19 are represented by red dots, while those conditions significantly associated with the development of mild COVID-19 are represented in blue (p < 0.05). HIV human immunodeficiency virus, DM Diabetes mellitus, AHT arterial hypertension.

Discussion

Due to a global effort, the main knowledge on the effect of specific demographic and clinical characteristics on COVID-19 severity has been established36. Herein the modified WHO COVID ordinal outcomes scale, which stratifies mild, moderate and severe patients, was employed to analyse both protective and risk variables. Other studies focused mainly on the severe states of the disease have selected additional sub-classifications37. Our study corroborates that age and sex are the two characteristics with the highest influence on COVID-19 severity as has been described3,4. Regarding comorbidities, the presence of oncological disease with metastasis, diabetes with organ damage, dementia, obesity and hypertension, in decreasing order of importance, significantly influence the risk of severe COVID-19 complications in our model, as previously reported2,4.

The finding that LHIV is an independent protective factor in our cohort is remarkable. In contrast, the largest study on the effect of COVID-19 on people LHIV showed that HIV infection was an independent risk factor for poor prognosis38. However, this study recognized that having an undetectable viral load and being on antiretroviral treatment (ART) greatly reduced the risk of worse disease onset, which has been validated in other Spanish LHIV cohorts39. Additionally, this study also indicated that other patient features, such as age and health quality, are factors that notably affect COVID-19 severity. Patients LHIV included herein presented a lower average age (49.9 ± 11.6 years) compared to those in the general population (63.8 ± 16.6 years) and presented a very high rate of immune virologic control, since almost all of them received ART treatment. Thus, we interpret the detected protective effect as a consequence of a greater supervision, concomitant ART treatment, and good immunological state of the patients prior to COVID-19 infection.

Heterogeneity in clinical response to SARS-CoV-2 that could not be explained by these clinical variables led us to study the influence of certain SNPs on the severity of infection and outcome in Spanish patients, focusing on the impact of genetic variants of genes involved in the IFN-I signalling pathway and the VIP/VPAC axis. We found that the TLR7 rs3853839-GG genotype was the greatest risk factor for disease severity, in agreement with recently described data40,41. This variant is located in the 3' untranslated region (UTR) and increases TLR7 transcripts in peripheral blood mononuclear cells (PBMC) from carriers with systemic lupus erythematosus (SLE)42, HCV-infected patients43 and COVID-19 patients44. In addition, rare TLR7 missense variants have been described in 4 young male patients with severe COVID-19 whose PBMCs displayed impaired type I and II IFN responses26 and Asano and colleagues reported TLR7 deficiency in 1% of men under 60 years with life-threatening COVID-1945. Moreover, Fallerini et al. described that TLR7 loss-of-function variants were present in 2% of young male patients thus establishing TLR7 as the most important susceptibility gene for life-threatening disease46.

Recently, we have described a close interaction between TLR7 expression and the IFN-I signalling pathway mediated through TYK247. Among the TYK2 SNPs evaluated herein, rs8108236-AA and rs280519-AG appear to be protective while rs280500-AG seems to increase the risk of COVID-19 severity. TYK2 rs8108236-AA genotype is rare and was only found in nine patients (Table S3). This is a splicing variant located in the intronic position chr19:10355156 that could exert an influence on expression changes. Additionally, TYK2 rs280519 is located 7 bp away from the start of intron 11 in a highly conserved interspecies region48, suggesting an important role in the function of the protein. In this case, the AG and AA genotypes are both present at equal frequency in the European population. Other variants assessed in our model, reported previously to have a protective effect in autoimmune diseases, such as TYK2 rs1272027048,49, rs12720356 and rs3453644350,51 were not found to be significant to predict COVID-19 severity, although the latter is a missense variant described as a risk allele for mycobacteria and viral infection30 and was associated to hospitalization due to SARS-CoV-2 infection in another study32. Similarly, severity is not influenced by the rs2304256 variant in our setting, in contrast with the poor outcome found in COVID-19 Brazilian patients, especially among female and non-white populations52. In our research, we found that TYK2 rs280500-AG increased the risk of COVID-19 severity, although the effect of this intronic variant on protein function is not known and it has not been previously associated with viral infection.

Downstream TYK2 in the IFN-I signalling pathway is OAS1, involved in the early antiviral response by degrading viral RNA53. We found the missense variant rs1131454-AA associated with disease severity, in agreement with previous reports relating this variant to COVID-19 hospitalization54,55 or increased risk for Alzheimer's disease56. In fact, this variant appears associated with this neurodegenerative disease (OR 2.58 [95% CI 1.22–5.46]; p = 0.013) in our cohort. Moreover, OAS1 rs1131454-AA achieved significant association with COVID-19 severity when correcting the model with dementia and other comorbidities, ensuring the independent effect of this SNP on clinical outcome. OAS1 rs2660 was previously associated with a lower risk of SARS-CoV-2 viremia24, but we did not find an association with disease outcome.

Altogether, these results reinforce the importance of timing in the host type I IFN response to control viral infection57; if this response is poor in the early stages of infection due to missense or impaired-function variants in TLR7, TYK2 or/and OAS1 it could favour virus evasion mechanisms and result in severe disease1,25,58. However, the persistence of an elevated IFN-I secretion when TLR7 and TYK2 expression is increased could induce inflammatory tissue damage, also leading to a worse outcome. Then, the fine-tuning of TLR7 and TYK2 expression is crucial to avoid triggering IFN-I mediated pathological processes.

Regarding VIP, we have shown that patients carrying the rs688136-CC genotype had a lower probability to develop severe COVID-19. Previous studies of our group described that the expression of this variant, located in the 3' UTR region, is higher in homozygous patients with early arthritis19. Elevated serum VIP levels correlated with a better outcome and response to treatments in these patients59. Lower serum VIP levels are present in patients with severe COVID-1960, therefore, high serum VIP could protect from a worst outcome in both IMID and COVID-19.

In conclusion, genetic variants in TYK2 (rs8108236 and rs280519) and VIP (rs688136) were associated with a better outcome of COVID-19. In contrast, TLR7 rs3853839, TYK2 rs280500 and OAS1 rs1131454 were identified as risk factors predicting higher disease severity. All these results improved the severity predictive model based on the patient's clinical features and comorbidities, helping to explain the variability in COVID-19 outcome within our population.

Materials and methods

Study design and population

This is a retrospective observational study including patients with COVID-19 treated at the University Hospital La Princesa from March 29th, 2020 to September 14th, 2021, before the vaccination campaign started in Spain (see results for detailed description of number of patients). Patients were included in the study if COVID-19 infection was confirmed by real-time polymerase chain reaction (RT-PCR) on nasopharyngeal samples or by serological testing, and if they were older than 18 years and had given informed consent. Blood samples of admitted patients were collected during their hospitalization while those treated as outpatients were recruited when the pandemic situation did not pose a risk to their health.

Probes and genotyping

Total DNA was extracted from peripheral blood using MagNA Pure 2.0 and MagNA Pure LC DNA Isolation Kit (Roche Life Science, Basel, Switzerland). Concentration and integrity were measured with NanoDrop ND-1000 (Thermo Fisher Scientific). Genotyping was performed at Parque Científico of Autónoma University of Madrid (UAM, Campus Cantoblanco, Madrid) using QuantStudio 12 k Flex, TaqMan™ Genotyping Master Mix and TaqMan™ customized 384 plates (all from Applied Biosystems, Thermo Fisher Scientific, Walthman, MA, USA), using individual probes, duplicate samples and negative controls to verify assay´s accuracy. Allelic discrimination was automatically defined by the TaqMan™ SNP Genotyping App (within Thermo Fisher Connect™, Applied Biosystems™ ANALYSIS SOFTWARE, Genotyping Analysis Module, version 4.1 was employed), based on allele-specific fluorescence. The assessed SNPs and their predesigned TaqMan™ probes and primer sequences are detailed in Table S2.

Variables

Data were extracted retrospectively from electronic medical records and included in a database in a pseudo-anonymized/codified way by removing all identifiable information to ensure the privacy of the patients.

All variables collected can be classified into six groups: demographic data, COVID-19-related clinical data, comorbidities, pharmacological treatment before and during the hospitalization and laboratory parameters. Laboratory parameters and COVID-19 pre-treatments were collected on admission day and according to pre-existing pathologies, respectively (Table S4). Additionally, variables were registered during patient hospitalization period or, in the case of outpatients, at the time of their visit to the emergency department.

The main outcome considered in the study was COVID-19 severity, assessed following a modified version of the 8-point World Health Organization (WHO) Ordinal Scale (WOS) to obtain the worst outcome for each patient (Table S5). According to this scoring system, a categorical outcome variable was elaborated by pooling patients in three levels: mild for 1, 2 and 3 WOS score, moderate for 4, and severe for 5, 6 and 7. In addition, in order to establish a more detailed comparison, among comorbidity variables, two of them were considered categorical instead of binary: diabetes (0: diabetes absence; 1: diabetes without complications; 2: diabetes with end organ damage) and tumors (0: tumor absence; 1: non metastatic solid tumor; 2: metastatic solid tumor).

Statistical analysis

Statistical analyses were performed using Stata 14.0 for Windows (StataCorp LP, College Station, TX, USA). Those quantitative variables with non-normal distribution were represented as median and interquartile range (IQR), and the Mann Whitney or Kruskal–Wallis tests were used to analyse significant differences. Quantitative variables with gaussian distribution were described as mean and standard deviation. Qualitative variables were described as proportions, and the χ2 test was used to compare categorical variables.

In order to identify those variables associated with variation of COVID-19 severity we fitted an ordered logistic regression analysis (command ologit of Stata), considering the dependent variable the WHO-severity scale grouped in Mild (levels 1 to 3), Moderate (level 4) and Severe (levels 5 to 7) as previously described61. The first model was performed by adding all sociodemographic variables, comorbidities and treatments previous to SARS-CoV-2 infection that achieved a p-value < 0.15 in the bivariate analysis (Table S6). The final clinical model was reached through backward stepwise removal of variables with p-value > 0.15, based on the Akaike information criterion (AIC)62. Once the best model was obtained, the different SNPs were forced in the model in order to determine whether there was an association with COVID-19 severity or not, using as reference the global major allele established in the Ensembl genome database. All those SNPs that achieved a p-value < 0.15 with this approach were included in the final model combining clinical and genetic variables, which was constructed as previously described for the clinical model. Finally, we evaluated whether the clinical model and the final model (with clinical and genetic variables) were different by AIC, R2 and ANOVA.

Supplementary Information

Supplementary Information.

Supplementary Information

The online version contains supplementary material available at 10.1038/s41598-024-71476-2.

Acknowledgements

We thank Dr. Manuel Gómez (IIS-Princesa) for editing the manuscript and the Fundación de Investigación Biomédica (FIB) administrative staff for support. This study was funded with grants: “Fondos Supera COVID19” by Banco Santander and CRUE to CM-C and RPG; RD21/0002/0027, PI18/0371 and PI21/00526 to IG-Á; PI19/00096 and PI22/00428 to EF-R and RICORS RD21/0002/0004 to RPG from Ministerio de Ciencia e Innovación (Instituto de Salud Carlos III, ISCIII), co-funded by European Regional Development Fund (ERDF) “A way to make Europe”; and co-financed by the Community of Madrid (CAM) through the COVID 2019 Aid to IdeS. The work of ER-V and AM-J was funded by Rio-Hortega grants CM19/00149 and CM19/00254, respectively, from the Ministerio de Ciencia e Innovación (Instituto de Salud Carlos III, ISCIII) and co-funded by The ERDF "A way to make Europe"; GV-G and PD-F were co-financed by ISCIII and the European Social Fund (PFIS grants FI20/00090 and FI19/00092, respectively). PZ was financed by Universidad Autónoma de Madrid, Margarita Salas contract, grants for the requalification of the Spanish university system. EA-C and AN-G were financed by INVESTIGO (2022-C23.I01.P03.S0020-0000031) and INVESTIGO CAM (09-PIN1-00015.6/2022), by Ministerio de Ciencia e Innovación and CAM respectively, both financed by the European Union's Recovery, Transformation and Resilience Plan and NextGenerationEU.

Author contributions

P.D.-W., S.C.-O.: conceptualization, writing—original draft, data curation, investigation, formal analysis, methodology, visualization, writing—review and editing. E.R.-V.: conceptualization, writing—original draft, data curation, investigation, formal analysis, methodology, software, validation, visualization, writing—review and editing. E.A.-C., A.N.-G., F.A.-S., A.M.-J.: data curation, investigation, visualization, writing—review and editing. A.L.: conceptualization, writing—original draft, methodology, visualization, writing—review and editing. N.M.: formal analysis, methodology, software, validation, visualization, writing—review and editing. D.R.-S., R.C.-R., P.D.-F., J.G.-R., L.R.-R., M.S.-A., J.A.-R., A.V.-M., C.R.-F., G.V.-G., P.Z.: data curation, investigation, visualization. I.S.: funding acquisition, project administration, resources, supervision, writing—review and editing. R.P.G., C.M.-C., R.G.-V.: conceptualization, funding acquisition, project administration, resources, supervision, writing—review and editing. I.G.-Á.: conceptualization, writing—original draft, formal analysis, methodology, software, validation, funding acquisition, project administration, resources, supervision, visualization, writing—review and editing. E.F.-R.: conceptualization, writing—original draft, funding acquisition, project administration, resources, supervision, visualization, writing—review and editing.

Data availability

The dataset from this publication has been deposited to the Zenodo database and assigned the identifier 10245797.

Competing interests

TFA-S has been consultant or investigator in clinical trials sponsored by the following pharmaceutical companies: Abbott, Alter, Aptatargets, Chemo, FAES, Farmalider, Ferrer, Galenicum, GlaxoSmithKline, Gilead, Italfarmaco, Janssen-427 Cilag, Kern, Normon, Novartis, Servier, Teva and Zambon. IG-Á reports personal fees from Lilly and Sanofi; personal fees and non-financial support from BMS; personal fees and non-financial support from Abbvie; research support, personal fees and non-financial support from Roche Laboratories; research support from Gebro Pharma; non-financial support from MSD, Pfizer and Novartis, not related to the submitted work. RGV declares educational or research grants for her institution from Abbvie, Lilly, Janssen, MSD, Novartis, Sanofi and UCB; consultancies/speaking personal fees from Abbvie, Biogen, MSD, Pfizer, Sandoz and UCB; non-financial support from Abbvie, Janssen, Lilly, MSD, Novartis, Pfizer and UCB, all outside the present work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Ethics

his study was approved by the Research Ethics Committee of University Hospital La Princesa, Madrid (register number 4070, March 30th 2020), and it was carried out following the ethical principles of the Declaration of Helsinki. All patients were informed about the study and gave oral or written consent to participate, which was registered in their electronic clinical chart. Due to the COVID-19 pandemic emergency, oral consent was accepted as proposed by the AEMPS (Agencia Española de Medicamentos y Productos Sanitarios, The Spanish Agency for Medicines and Medical Devices) in April 2020. Due to the periodical medical supervision, the written consent of the people living with HIV was subsequently obtained. This article was written following the STREGA (STrengthening the REporting of Genetic Association studies) guidelines (Table S7).

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Pablo Delgado-Wicke, Sara Fernández de Córdoba-Oñate, Isidoro González-Álvaro and Elena Fernández-Ruiz.

A list of authors and their affiliations appears at the end of the paper.
==== Refs
References

1. Hadjadj J Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients Science 2020 369 718 724 10.1126/science.abc6027 32661059
Hadjadj, J. et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 369, 718–724 (2020).32661059 10.1126/science.abc6027
2. Wu Z McGoogan JM Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for disease control and prevention JAMA 2020 323 1239 1242 10.1001/jama.2020.2648 32091533
Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for disease control and prevention. JAMA 323, 1239–1242 (2020).32091533 10.1001/jama.2020.2648
3. Zhang JJY Lee KS Ang LW Leo YS Young BE Risk factors for severe disease and efficacy of treatment in patients infected with COVID-19: A systematic review, meta-analysis, and meta-regression analysis Clin. Infect Dis. 2020 71 2199 2206 10.1093/cid/ciaa576 32407459
Zhang, J. J. Y., Lee, K. S., Ang, L. W., Leo, Y. S. & Young, B. E. Risk factors for severe disease and efficacy of treatment in patients infected with COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Clin. Infect Dis. 71, 2199–2206 (2020).32407459 10.1093/cid/ciaa576
4. Zhou F Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study Lancet 2020 395 1054 1062 10.1016/S0140-6736(20)30566-3 32171076
Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 395, 1054–1062 (2020).32171076 10.1016/S0140-6736(20)30566-3
5. Siddiqi HK Mehra MR COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal J. Heart Lung Transplant. 2020 39 405 407 10.1016/j.healun.2020.03.012 32362390
Siddiqi, H. K. & Mehra, M. R. COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal. J. Heart Lung Transplant. 39, 405–407 (2020).32362390 10.1016/j.healun.2020.03.012
6. Tsai P-H Clinical manifestation and disease progression in COVID-19 infection J. Chin. Med. Assoc. 2021 84 3 8 10.1097/JCMA.0000000000000463 33230062
Tsai, P.-H. et al. Clinical manifestation and disease progression in COVID-19 infection. J. Chin. Med. Assoc. 84, 3–8 (2021).33230062 10.1097/JCMA.0000000000000463
7. Páramo JA Inflammatory response in relation to COVID-19 and other prothrombotic phenotypes Reumatol. Clin. (Engl. Ed.) 2022 18 1 4 10.1016/j.reuma.2020.06.004 35090606
Páramo, J. A. Inflammatory response in relation to COVID-19 and other prothrombotic phenotypes. Reumatol. Clin. (Engl. Ed.) 18, 1–4 (2022).35090606 10.1016/j.reuma.2020.06.004
8. Yang L Potential role of IFN-α in COVID-19 patients and its underlying treatment options Appl. Microbiol. Biotechnol. 2021 105 4005 4015 10.1007/s00253-021-11319-6 33950278
Yang, L. et al. Potential role of IFN-α in COVID-19 patients and its underlying treatment options. Appl. Microbiol. Biotechnol. 105, 4005–4015 (2021).33950278 10.1007/s00253-021-11319-6
9. Diebold SS Kaisho T Hemmi H Akira S Reis e Sousa C Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA Science 2004 303 1529 1531 10.1126/science.1093616 14976261
Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S. & Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529–1531 (2004).14976261 10.1126/science.1093616
10. Lund JM Recognition of single-stranded RNA viruses by Toll-like receptor 7 Proc. Natl. Acad. Sci. USA 2004 101 5598 5603 10.1073/pnas.0400937101 15034168
Lund, J. M. et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 101, 5598–5603 (2004).15034168 10.1073/pnas.0400937101
11. van der Sluis RM TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infection EMBO J. 2022 41 e109622 10.15252/embj.2021109622 35178710
van der Sluis, R. M. et al. TLR2 and TLR7 mediate distinct immunopathological and antiviral plasmacytoid dendritic cell responses to SARS-CoV-2 infection. EMBO J. 41, e109622 (2022).35178710 10.15252/embj.2021109622
12. Crosse KM Monson EA Beard MR Helbig KJ Interferon-stimulated genes as enhancers of antiviral innate immune signaling J. Innate Immun. 2018 10 85 93 10.1159/000484258 29186718
Crosse, K. M., Monson, E. A., Beard, M. R. & Helbig, K. J. Interferon-stimulated genes as enhancers of antiviral innate immune signaling. J. Innate Immun. 10, 85–93 (2018).29186718 10.1159/000484258
13. Schoggins JW Interferon-stimulated genes: What Do they all do? Annu. Rev. Virol. 2019 6 567 584 10.1146/annurev-virology-092818-015756 31283436
Schoggins, J. W. Interferon-stimulated genes: What Do they all do?. Annu. Rev. Virol. 6, 567–584 (2019).31283436 10.1146/annurev-virology-092818-015756
14. Gonciarz M Pawlak-Buś K Leszczyński P Owczarek W TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases Immunotherapy 2021 13 1135 1150 10.2217/imt-2021-0096 34235974
Gonciarz, M., Pawlak-Buś, K., Leszczyński, P. & Owczarek, W. TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases. Immunotherapy 13, 1135–1150 (2021).34235974 10.2217/imt-2021-0096
15. Hu X Li J Fu M Zhao X Wang W The JAK/STAT signaling pathway: From bench to clinic Signal Transduct. Target Ther. 2021 6 402 10.1038/s41392-021-00791-1 34824210
Hu, X., Li, J., Fu, M., Zhao, X. & Wang, W. The JAK/STAT signaling pathway: From bench to clinic. Signal Transduct. Target Ther. 6, 402 (2021).34824210 10.1038/s41392-021-00791-1
16. Muromoto R Shimoda K Oritani K Matsuda T Therapeutic advantage of Tyk2 inhibition for treating autoimmune and chronic inflammatory diseases Biol. Pharm. Bull. 2021 44 1585 1592 10.1248/bpb.b21-00609 34719635
Muromoto, R., Shimoda, K., Oritani, K. & Matsuda, T. Therapeutic advantage of Tyk2 inhibition for treating autoimmune and chronic inflammatory diseases. Biol. Pharm. Bull. 44, 1585–1592 (2021).34719635 10.1248/bpb.b21-00609
17. Gomariz RP An overview of VPAC receptors in rheumatoid arthritis: Biological role and clinical significance Front. Endocrinol. 2019 10 729 10.3389/fendo.2019.00729
Gomariz, R. P. et al. An overview of VPAC receptors in rheumatoid arthritis: Biological role and clinical significance. Front. Endocrinol. 10, 729 (2019).10.3389/fendo.2019.00729
18. Martínez C A Clinical approach for the use of VIP axis in inflammatory and autoimmune diseases Int. J. Mol. Sci. 2019 21 65 10.3390/ijms21010065 31861827
Martínez, C. et al. A Clinical approach for the use of VIP axis in inflammatory and autoimmune diseases. Int. J. Mol. Sci. 21, 65 (2019).31861827 10.3390/ijms21010065
19. Lamana A VIP/VPAC axis expression in immune-mediated inflammatory disorders: Associated miRNA signatures Int. J. Mol. Sci. 2022 23 8578 10.3390/ijms23158578 35955723
Lamana, A. et al. VIP/VPAC axis expression in immune-mediated inflammatory disorders: Associated miRNA signatures. Int. J. Mol. Sci. 23, 8578 (2022).35955723 10.3390/ijms23158578
20. He Y Zang N Liu E-M Vasoactive intestinal peptide: A potential target for antiviral therapy Sheng Li Xue Bao 2022 74 419 433 35770640
He, Y., Zang, N. & Liu, E.-M. Vasoactive intestinal peptide: A potential target for antiviral therapy. Sheng Li Xue Bao 74, 419–433 (2022).35770640
21. Mukherjee T Anticipated pharmacological role of Aviptadil on COVID-19 Environ. Sci. Pollut. Res. Int. 2022 29 8109 8125 10.1007/s11356-021-17824-5 34846667
Mukherjee, T. et al. Anticipated pharmacological role of Aviptadil on COVID-19. Environ. Sci. Pollut. Res. Int. 29, 8109–8125 (2022).34846667 10.1007/s11356-021-17824-5
22. Colona VL Vasiliou V Watt J Novelli G Reichardt JKV Update on human genetic susceptibility to COVID-19: Susceptibility to virus and response Hum. Genom. 2021 15 57 10.1186/s40246-021-00356-x
Colona, V. L., Vasiliou, V., Watt, J., Novelli, G. & Reichardt, J. K. V. Update on human genetic susceptibility to COVID-19: Susceptibility to virus and response. Hum. Genom. 15, 57 (2021).10.1186/s40246-021-00356-x
23. Villapalos-García G Transmembrane protease serine 2 (TMPRSS2) rs75603675, comorbidity, and sex are the primary predictors of COVID-19 severity Life Sci. Alliance 2022 5 e202201396 10.26508/lsa.202201396 35636966
Villapalos-García, G. et al. Transmembrane protease serine 2 (TMPRSS2) rs75603675, comorbidity, and sex are the primary predictors of COVID-19 severity. Life Sci. Alliance 5, e202201396 (2022).35636966 10.26508/lsa.202201396
24. Roy-Vallejo E Occurrence of SARS-CoV-2 viremia is associated with genetic variants of genes related to COVID-19 pathogenesis Front Med 2023 10 1215246 10.3389/fmed.2023.1215246
Roy-Vallejo, E. et al. Occurrence of SARS-CoV-2 viremia is associated with genetic variants of genes related to COVID-19 pathogenesis. Front Med 10, 1215246 (2023).10.3389/fmed.2023.1215246
25. Blanco-Melo D Imbalanced host response to SARS-CoV-2 drives development of COVID-19 Cell 2020 181 1036 1045.e9 10.1016/j.cell.2020.04.026 32416070
Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036-1045.e9 (2020).32416070 10.1016/j.cell.2020.04.026
26. van der Made CI Presence of genetic variants among young men with severe COVID-19 JAMA 2020 324 663 673 10.1001/jama.2020.13719 32706371
van der Made, C. I. et al. Presence of genetic variants among young men with severe COVID-19. JAMA 324, 663–673 (2020).32706371 10.1001/jama.2020.13719
27. Zhang Q Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 Science 2020 370 eabd4570 10.1126/science.abd4570 32972995
Zhang, Q. et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 370, eabd4570 (2020).32972995 10.1126/science.abd4570
28. Zhang Q Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia J. Exp. Med. 2022 219 e20220131 10.1084/jem.20220131 35708626
Zhang, Q. et al. Recessive inborn errors of type I IFN immunity in children with COVID-19 pneumonia. J. Exp. Med. 219, e20220131 (2022).35708626 10.1084/jem.20220131
29. Dupuis S Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency Nat. Genet. 2003 33 388 391 10.1038/ng1097 12590259
Dupuis, S. et al. Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat. Genet. 33, 388–391 (2003).12590259 10.1038/ng1097
30. Kreins AY Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome J. Exp. Med. 2015 212 1641 1662 10.1084/jem.20140280 26304966
Kreins, A. Y. et al. Human TYK2 deficiency: Mycobacterial and viral infections without hyper-IgE syndrome. J. Exp. Med. 212, 1641–1662 (2015).26304966 10.1084/jem.20140280
31. Ott N Faletti L Heeg M Andreani V Grimbacher B JAKs and STATs from a clinical perspective: Loss-of-function mutations, gain-of-function mutations, and their multidimensional consequences J. Clin. Immunol. 2023 43 1326 1359 10.1007/s10875-023-01483-x 37140667
Ott, N., Faletti, L., Heeg, M., Andreani, V. & Grimbacher, B. JAKs and STATs from a clinical perspective: Loss-of-function mutations, gain-of-function mutations, and their multidimensional consequences. J. Clin. Immunol. 43, 1326–1359 (2023).37140667 10.1007/s10875-023-01483-x
32. COVID-19 Host Genetics Initiative Mapping the human genetic architecture of COVID-19 Nature 2021 600 472 477 10.1038/s41586-021-03767-x 34237774
COVID-19 Host Genetics Initiative. Mapping the human genetic architecture of COVID-19. Nature 600, 472–477 (2021).34237774 10.1038/s41586-021-03767-x
33. Kousathanas A Whole-genome sequencing reveals host factors underlying critical COVID-19 Nature 2022 607 97 103 10.1038/s41586-022-04576-6 35255492
Kousathanas, A. et al. Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature 607, 97–103 (2022).35255492 10.1038/s41586-022-04576-6
34. Pairo-Castineira E Genetic mechanisms of critical illness in COVID-19 Nature 2021 591 92 98 10.1038/s41586-020-03065-y 33307546
Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in COVID-19. Nature 591, 92–98 (2021).33307546 10.1038/s41586-020-03065-y
35. Berg J Tyk2 as a target for immune regulation in human viral/bacterial pneumonia Eur. Respir. J. 2017 50 1601953 10.1183/13993003.01953-2016 28705941
Berg, J. et al. Tyk2 as a target for immune regulation in human viral/bacterial pneumonia. Eur. Respir. J. 50, 1601953 (2017).28705941 10.1183/13993003.01953-2016
36. Tian W Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis J. Med. Virol. 2020 92 1875 1883 10.1002/jmv.26050 32441789
Tian, W. et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. J. Med. Virol. 92, 1875–1883 (2020).32441789 10.1002/jmv.26050
37. Bautista-Becerril B High expression levels of miR-21-5p in younger hospitalized COVID-19 patients are associated with mortality and critical disease Int. J. Mol. Sci. 2023 24 10112 10.3390/ijms241210112 37373259
Bautista-Becerril, B. et al. High expression levels of miR-21-5p in younger hospitalized COVID-19 patients are associated with mortality and critical disease. Int. J. Mol. Sci. 24, 10112 (2023).37373259 10.3390/ijms241210112
38. Bertagnolio S Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: Analysis of data from the WHO Global Clinical Platform of COVID-19 Lancet HIV 2022 9 e486 e495 10.1016/S2352-3018(22)00097-2 35561704
Bertagnolio, S. et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: Analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV 9, e486–e495 (2022).35561704 10.1016/S2352-3018(22)00097-2
39. Del Amo J Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: A cohort study Ann. Intern. Med. 2020 173 536 541 10.7326/M20-3689 32589451
Del Amo, J. et al. Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy: A cohort study. Ann. Intern. Med. 173, 536–541 (2020).32589451 10.7326/M20-3689
40. Martínez-Gómez LE Implication of myddosome complex genetic variants in outcome severity of COVID-19 patients J. Microbiol. Immunol. Infect. 2023 56 939 950 10.1016/j.jmii.2023.06.002 37365052
Martínez-Gómez, L. E. et al. Implication of myddosome complex genetic variants in outcome severity of COVID-19 patients. J. Microbiol. Immunol. Infect. 56, 939–950 (2023).37365052 10.1016/j.jmii.2023.06.002
41. Naushad SM Mandadapu G Ramaiah MJ Almajhdi FN Hussain T The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants Sci. Rep. 2023 13 13078 10.1038/s41598-023-40114-8 37567916
Naushad, S. M., Mandadapu, G., Ramaiah, M. J., Almajhdi, F. N. & Hussain, T. The role of TLR7 agonists in modulating COVID-19 severity in subjects with loss-of-function TLR7 variants. Sci. Rep. 13, 13078 (2023).37567916 10.1038/s41598-023-40114-8
42. Shen N Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus Proc. Natl. Acad. Sci. USA 2010 107 15838 15843 10.1073/pnas.1001337107 20733074
Shen, N. et al. Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 107, 15838–15843 (2010).20733074 10.1073/pnas.1001337107
43. Liao T-L Hepatitis C virus-induced exosomal microRNAs and toll-like receptor 7 polymorphism regulate B-cell activating factor mBio 2021 12 e0276421 10.1128/mBio.02764-21 34724826
Liao, T.-L. et al. Hepatitis C virus-induced exosomal microRNAs and toll-like receptor 7 polymorphism regulate B-cell activating factor. mBio 12, e0276421 (2021).34724826 10.1128/mBio.02764-21
44. El-Hefnawy SM COVID-19 susceptibility, severity, clinical outcome and Toll-like receptor (7) mRNA expression driven by TLR7 gene polymorphism (rs3853839) in middle-aged individuals without previous comorbidities Gene Rep. 2022 27 101612 10.1016/j.genrep.2022.101612 35463461
El-Hefnawy, S. M. et al. COVID-19 susceptibility, severity, clinical outcome and Toll-like receptor (7) mRNA expression driven by TLR7 gene polymorphism (rs3853839) in middle-aged individuals without previous comorbidities. Gene Rep. 27, 101612 (2022).35463461 10.1016/j.genrep.2022.101612
45. Asano T X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19 Sci. Immunol. 2021 6 eabl4348 10.1126/sciimmunol.abl4348 34413140
Asano, T. et al. X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19. Sci. Immunol. 6, eabl4348 (2021).34413140 10.1126/sciimmunol.abl4348
46. Fallerini C Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study Elife 2021 10 e67569 10.7554/eLife.67569 33650967
Fallerini, C. et al. Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study. Elife 10, e67569 (2021).33650967 10.7554/eLife.67569
47. Bodega-Mayor I Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling Cell Mol. Life Sci 2024 81 199 10.1007/s00018-024-05234-y 38683377
Bodega-Mayor, I. et al. Tyrosine kinase 2 modulates splenic B cells through type I IFN and TLR7 signaling. Cell Mol. Life Sci 81, 199 (2024).38683377 10.1007/s00018-024-05234-y
48. Cunninghame Graham DS Akil M Vyse TJ Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families Rheumatology (Oxford) 2007 46 927 930 10.1093/rheumatology/kel449 17384181
Cunninghame Graham, D. S., Akil, M. & Vyse, T. J. Association of polymorphisms across the tyrosine kinase gene, TYK2 in UK SLE families. Rheumatology (Oxford) 46, 927–930 (2007).17384181 10.1093/rheumatology/kel449
49. Hellquist A Evidence for genetic association and interaction between the TYK2 and IRF5 genes in systemic lupus erythematosus J. Rheumatol. 2009 36 1631 1638 10.3899/jrheum.081160 19567624
Hellquist, A. et al. Evidence for genetic association and interaction between the TYK2 and IRF5 genes in systemic lupus erythematosus. J. Rheumatol. 36, 1631–1638 (2009).19567624 10.3899/jrheum.081160
50. Eyre S High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis Nat. Genet. 2012 44 1336 1340 10.1038/ng.2462 23143596
Eyre, S. et al. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat. Genet. 44, 1336–1340 (2012).23143596 10.1038/ng.2462
51. Diogo D TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits PLoS ONE 2015 10 e0122271 10.1371/journal.pone.0122271 25849893
Diogo, D. et al. TYK2 protein-coding variants protect against rheumatoid arthritis and autoimmunity, with no evidence of major pleiotropic effects on non-autoimmune complex traits. PLoS ONE 10, e0122271 (2015).25849893 10.1371/journal.pone.0122271
52. Dieter C Polymorphisms in ACE1, TMPRSS2, IFIH1, IFNAR2, and TYK2 genes are associated with worse clinical outcomes in COVID-19 Genes 2022 14 29 10.3390/genes14010029 36672770
Dieter, C. et al. Polymorphisms in ACE1, TMPRSS2, IFIH1, IFNAR2, and TYK2 genes are associated with worse clinical outcomes in COVID-19. Genes 14, 29 (2022).36672770 10.3390/genes14010029
53. Choi UY Kang J-S Hwang YS Kim Y-J Oligoadenylate synthase-like (OASL) proteins: Dual functions and associations with diseases Exp. Mol. Med. 2015 47 e144 10.1038/emm.2014.110 25744296
Choi, U. Y., Kang, J.-S., Hwang, Y. S. & Kim, Y.-J. Oligoadenylate synthase-like (OASL) proteins: Dual functions and associations with diseases. Exp. Mol. Med. 47, e144 (2015).25744296 10.1038/emm.2014.110
54. Tanimine N Identification of aggravation-predicting gene polymorphisms in coronavirus disease 2019 patients using a candidate gene approach associated with multiple phase pathogenesis: A study in a Japanese City of 1 million people Crit. Care Explor. 2021 3 e0576 10.1097/CCE.0000000000000576 34765983
Tanimine, N. et al. Identification of aggravation-predicting gene polymorphisms in coronavirus disease 2019 patients using a candidate gene approach associated with multiple phase pathogenesis: A study in a Japanese City of 1 million people. Crit. Care Explor. 3, e0576 (2021).34765983 10.1097/CCE.0000000000000576
55. Banday AR Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries Nat. Genet. 2022 54 1103 1116 10.1038/s41588-022-01113-z 35835913
Banday, A. R. et al. Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries. Nat. Genet. 54, 1103–1116 (2022).35835913 10.1038/s41588-022-01113-z
56. Magusali N A genetic link between risk for Alzheimer’s disease and severe COVID-19 outcomes via the OAS1 gene Brain 2021 144 3727 3741 10.1093/brain/awab337 34619763
Magusali, N. et al. A genetic link between risk for Alzheimer’s disease and severe COVID-19 outcomes via the OAS1 gene. Brain 144, 3727–3741 (2021).34619763 10.1093/brain/awab337
57. Park A Iwasaki A Type I and Type III interferons—Induction, signaling, evasion, and application to combat COVID-19 Cell Host Microbe 2020 27 870 878 10.1016/j.chom.2020.05.008 32464097
Park, A. & Iwasaki, A. Type I and Type III interferons—Induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe 27, 870–878 (2020).32464097 10.1016/j.chom.2020.05.008
58. Zhang X Viral and host factors related to the clinical outcome of COVID-19 Nature 2020 583 437 440 10.1038/s41586-020-2355-0 32434211
Zhang, X. et al. Viral and host factors related to the clinical outcome of COVID-19. Nature 583, 437–440 (2020).32434211 10.1038/s41586-020-2355-0
59. Seoane IV Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis Sci. Rep. 2018 8 2035 10.1038/s41598-018-20400-6 29391448
Seoane, I. V. et al. Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis. Sci. Rep. 8, 2035 (2018).29391448 10.1038/s41598-018-20400-6
60. Temerozo JR VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells J. Leukoc. Biol. 2022 111 1107 1121 10.1002/JLB.5COVA1121-626R 35322471
Temerozo, J. R. et al. VIP plasma levels associate with survival in severe COVID-19 patients, correlating with protective effects in SARS-CoV-2-infected cells. J. Leukoc. Biol. 111, 1107–1121 (2022).35322471 10.1002/JLB.5COVA1121-626R
61. Su Y Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19 Cell 2020 183 1479 1495.e20 10.1016/j.cell.2020.10.037 33171100
Su, Y. et al. Multi-omics resolves a sharp disease-state shift between mild and moderate COVID-19. Cell 183, 1479-1495.e20 (2020).33171100 10.1016/j.cell.2020.10.037
62. Akaike H A new look at the statistical model identification Sel. Pap. Hirotugu Akaike 1974 10.1007/978-1-4612-1694-0_16
Akaike, H. A new look at the statistical model identification. Sel. Pap. Hirotugu Akaike10.1007/978-1-4612-1694-0_16 (1974).10.1007/978-1-4612-1694-0_16
